Enhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear
The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
The endogenous cannabinoid (eCB) system represents a major therapeutic target for the treatment of a variety of anxiety-related disorders. A recent study has demonstrated that pharmacologic or genetic disruption of CB1-receptor-mediated neurotransmission decreases the extinction of conditioned fear in mice. Here, we examined whether CB1 blockade would similarly disrupt extinction in rats, using fear-potentiated startle as a measure of conditioned fear. We also examined whether pharmacologic enhancement of CB1 activation would lead to enhancements in extinction. Our results indicate that systemic administration of the CB1 antagonist rimonabant (SR141716A) prior to extinction training led to significant, dose-dependent decreases in extinction. While the administration of the CB1 agonist WIN 55,212-2 did not appear to affect extinction, administration of AM404, an inhibitor of eCB breakdown and reuptake, led to dose-dependent enhancements in extinction. In addition to showing decreased fear 1 and 24 h after extinction training, AM404-treated animals showed decreased shock-induced reinstatement of fear. Control experiments demonstrated that the effects of AM404 could not be attributed to alterations in the expression of conditioned fear, locomotion, shock reactivity, or baseline startle, as these parameters seemed unchanged by AM404. Furthermore, coadministration of rimonabant with AM404 blocked this enhancement of extinction, suggesting that AM404 was acting to increase CB1 rece…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The endocannabinoid system has also been implicated in conditioned fear extinction and represents an additional area of exploration for facilitating extinction and prevention of fear return.”
From Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors (2014) · cites this paper as [83]
In the citing paper
“Chhatwal et al. (83) showed that enhanced cannabinoid receptor CB1 activation (via administration of AM404, an agent that prevents endocannabinoid degradation and reuptake) facilitated within-session and between-session extinction of fear-potentiated startle as well as reinstatement in mice (83).”
From Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors (2014) · cites this paper as [83]
In the citing paper
“Activating CB1R via systemic or intra-hippocampal or -mPFC administration of either the CB1R agonist, WIN55212-2, the ECB reuptake blocker, AM404, or AEA itself has been shown to facilitate rodent fear extinction, in most cases without affecting conditioned fear [89,95–98] (but see [90]).”
From Amygdala FAAH and anandamide: mediating protection and recovery from stress (2013) · cites this paper as [96]
Citations
Cites
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“Recent studies of CB1 knockout mice have demonstrated that the genetic deletion of the CB1 receptor leads to increased anxiety in several well-studied measures (Haller et al, 2002, 2004a, b; Martin et al, 2002).”
BackgroundRole of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 3×
“Manipulation of the endogenous cannabinoid (eCB) system has become a major focus of current research, especially in the search for novel therapeutics to treat many common mental illnesses, including anxiety disorders, depression, and drug addiction (Porter and Felder, 2001; Kathuria et al, 2003).”
BackgroundResultKatona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218 · cited 2×
“…by the dense expression of the CB1 receptor in regions known to be important for anxiety and emotional learning, including the amygdala, hippocampus, and throughout the mesolimbic dopamine reward system (Katona et al, 1999, 2000, 2001; Freund et al, 2003; van der Stelt and Di Marzo, 2003).”
BackgroundResultMemory Reconsolidation and Extinction Have Distinct Temporal and Biochemical Signatures
Suzuki, A., Josselyn, S. A., Frankland, P. W., Masushige, S., Silva, A. J., & Kida, S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5491-03.2004 · Cited by 1,127
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063 · cited 1×
“Follow-up clinical trials have now demonstrated that this approach may be successful in humans as well (Ressler et al, 2004; Rothbaum and Davis, 2003).”
BackgroundSelf-citationMarsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937 · cited 1×
“These hybridization results are in close agreement with previous studies using immunohistochemical and hybridization techniques (Katona et al, 1999; Marsicano and Lutz, 1999; McDonald and Mascagni, 2001).”
ResultBehavioral and Neural Analysis of Extinction
Myers, K. M., & Davis, M. (2002) · Neuron · doi:10.1016/s0896-6273(02)01064-4 · Cited by 918 · cited 1×
“Reinstatement of fear is one of the principle behavioral processes upon which the idea is based that extinction does not lead to an ‘erasure’ of memory, but rather to a parallel inhibitory process that masks the previous fear memory (for a review, see Myers and Davis, 2002).”
BackgroundSelf-citationWalker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Self-citation
Cited by
Items 101–200 of 417
Hübner, C., Bosch, D., Gall, A., Lüthi, A., & Ehrlich, I. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00064 · Cited by 115
de Bitencourt, R. M., & Takahashi, R. N. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00502 · Cited by 111
Gee, D. G., Fetcho, R. N., Jing, D., Li, A., Glatt, C. E., Drysdale, A. T., Cohen, A. O., Dellarco, D. V., Yang, R. R., Dale, A. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600013113 · Cited by 100
Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System
Augustin, S. M., & Lovinger, D. M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00508 · Cited by 110
Solinas, M., Panlilio, L. V., Tanda, G., Makriyannis, A., Matthews, S. A., & Goldberg, S. R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300754 · Cited by 109
Modulation of Fear Extinction by Stress, Stress Hormones and Estradiol: A Review
Stockhorst, U., & Antov, M. I. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00359 · Cited by 85
The effect of yohimbine on the extinction of conditioned fear: A role for context.
Morris, R. W., & Bouton, M. E. (2007) · Behavioral Neuroscience · doi:10.1037/0735-7044.121.3.501 · Cited by 100
Lin, H.-C., Mao, S.-C., & Gean, P.-W. (2006) · Learning & Memory · doi:10.1101/lm.217006 · Cited by 107
Nicotine and cannabinoids: parallels, contrasts and interactions
VIVEROS, M., MARCO, E., & FILE, S. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.08.002 · Cited by 106
From endocannabinoid profiling to ‘endocannabinoid therapeutics’
Ligresti, A., Petrosino, S., & Marzo, V. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.615 · Cited by 106
Briscione, M. A., Jovanovic, T., & Norrholm, S. D. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00088 · Cited by 105
Saito, V. M., Wotjak, C. T., & Moreira, F. A. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500004 · Cited by 103
The role of CB1 receptors in psychostimulant addiction
Wiskerke, J., Pattij, T., Schoffelmeer, A. N. M., & De Vries, T. J. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00109.x · Cited by 93
Finn, D. P. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.05.011 · Cited by 101
Morena, M., Berardi, A., Colucci, P., Palmery, M., Trezza, V., Hill, M. N., & Campolongo, P. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.305 · Cited by 101
Atsak, P., Roozendaal, B., & Campolongo, P. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.047 · Cited by 98
Ganon-Elazar, E., & Akirav, I. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.01.014 · Cited by 98
Infusion of cannabidiol into infralimbic cortex facilitates fear extinction via CB1 receptors
Monte, F. H. D., de Souza, R. R., de Bitencourt, R. M., Kroon, J. A. V., & Takahashi, R. N. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.04.045 · Cited by 97
Role of Endocannabinoid Signaling in Anxiety and Depression
Patel, S., & Hillard, C. J. (2009) · Current Topics in Behavioral Neurosciences · doi:10.1007/978-3-540-88955-7_14 · Cited by 83
Fear relief—toward a new conceptual frame work and what endocannabinoids gotta do with it
Riebe, C. J. N., Pamplona, F. A., Kamprath, K., & Wotjak, C. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.11.057 · Cited by 94
Endocannabinoid-mediated synaptic plasticity and addiction-related behavior
Sidhpura, N., & Parsons, L. H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.034 · Cited by 92
Role of endocannabinoids in the hippocampus and amygdala in emotional memory and plasticity
Segev, A., Korem, N., Zer‐Aviv, T. M., Abush, H., Lange, R., Sauber, G., Hillard, C. J., & Akirav, I. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0135-4 · Cited by 91
de Bitencourt, R. M., Pamplona, F. A., & Takahashi, R. N. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.039 · Cited by 90
Fernández‐Suárez, D., Celorrio, M., Riezu‐Boj, J. I., Ugarte, A., Pacheco, R., González, H., Oyarzábal, J., Hillard, C. J., Franco, R., & Aymerich, M. S. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.05.021 · Cited by 90
Chhatwal, J. P., Gutman, A. R., Maguschak, K. A., Bowser, M. E., Yang, Y., Davis, M., & Ressler, K. J. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.97 · Cited by 90
Self-citationFear extinction in rodents: basic insight to clinical promise
Barad, M. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.10.005 · Cited by 90
Endocannabinoids: Effectors of glucocorticoid signaling
Balsevich, G., Petrie, G. N., & Hill, M. N. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.07.005 · Cited by 90
Bailey, C. R., Cordell, E., Sobin, S. M., & Neumeister, A. (2013) · CNS Drugs · doi:10.1007/s40263-013-0051-4 · Cited by 89
Chronic Pain and Psychiatric Conditions
Johnston, K. J. A., & Huckins, L. M. (2022) · Complex Psychiatry · doi:10.1159/000527041 · Cited by 87
Kamprath, K., Romo-Parra, H., Häring, M., Gaburro, S., Doengi, M., Lutz, B., & Pape, H.-C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.196 · Cited by 86
Roche, M., O'Connor, E., Diskin, C., & Finn, D. P. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05861.x · Cited by 83
Neumeister, A., Seidel, J., Ragen, B., & Pietrzak, R. H. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.10.012 · Cited by 83
Sex‐dependent effects of endocannabinoid modulation of conditioned fear extinction in rats
Morena, M., Nastase, A. S., Santori, A., Cravatt, B. F., Shansky, R. M., & Hill, M. N. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15341 · Cited by 82
Berardi, A., Schelling, G., & Campolongo, P. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.024 · Cited by 82
Resstel, L. B. M., Lisboa, S. F. D. S., de Aguiar, D. C., Corrêa, F. M. D. A., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1156-1 · Cited by 82
Endocannabinoid modulation of fear responses: learning and state-dependent performance effects
Reich, C., Mohammadi, M., & Alger, B. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107083999 · Cited by 72
Yamada, D., Zushida, K., Wada, K., & Sekiguchi, M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.86 · Cited by 80
Whittle, N., Schmuckermair, C., Gunduz Cinar, O., Hauschild, M., Ferraguti, F., Holmes, A., & Singewald, N. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.001 · Cited by 76
Modulation of Fear and Anxiety by the Endogenous Cannabinoid System
Chhatwal, J. P., & Ressler, K. J. (2007) · CNS Spectrums · doi:10.1017/s1092852900020939 · Cited by 69
Self-citationKuhnert, S., Meyer, C., & Koch, M. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.05.002 · Cited by 79
Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1
Heitland, I., Klumpers, F., Oosting, R. S., Evers, D. J. J., Kenemans, J. L., & Baas, J. M. P. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.90 · Cited by 77
Developmental regulation of fear learning and anxiety behavior by endocannabinoids
Lee, T. T. ‐., Hill, M. N., & Lee, F. S. (2016) · Genes, Brain and Behavior · doi:10.1111/gbb.12253 · Cited by 67
Morena, M., Aukema, R. J., Leitl, K. D., Rashid, A. J., Vecchiarelli, H. A., Josselyn, S. A., & Hill, M. N. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2251-18.2018 · Cited by 76
Marco, E. M., & Laviola, G. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111408459 · Cited by 65
Fear as a translational mechanism in the psychopathology of anorexia nervosa
Murray, S. B., Strober, M., Craske, M. G., Griffiths, S., Levinson, C. A., & Strigo, I. A. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.10.013 · Cited by 75
Bukalo, O., Pinard, C. R., & Holmes, A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12779 · Cited by 67
Ney, L. J., Matthews, A., Bruno, R., & Felmingham, K. L. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.07.006 · Cited by 66
Marco, E. M., Granstrem, O., Moreno, E., Llorente, R., Adriani, W., Laviola, G., & Viveros, M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.013 · Cited by 74
2-arachidonoylglycerol signaling impairs short-term fear extinction
Hartley, N. D., Gunduz-Cinar, O., Halladay, L., Bukalo, O., Holmes, A., & Patel, S. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.26 · Cited by 65
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson’s disease
Celorrio, M., Fernández‐Suárez, D., Rojo-Bustamante, E., Echeverry‐Alzate, V., Ramírez, M. J., Hillard, C. J., López‐Moreno, J. A., Maldonado, R. J., Oyarzábal, J., Franco, R., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.06.010 · Cited by 73
Testing the effects of Δ9-THC and D-cycloserine on extinction of conditioned fear in humans
Klumpers, F., Denys, D., Kenemans, J. L., Grillon, C., van der Aart, J., & Baas, J. M. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431624 · Cited by 72
“For THC, evidence from preclinical studies shows that relatively low doses of CB1 agonists are most effective in facilitating extinction (Chhatwal et al., 2005; Pamplona et al., 2006), and that high doses are anxiogenic (Moreira and Lutz, 2008; Viveros et al., 2005).”
BackgroundMethodInfluentialWise, L. E., Long, K. A., Abdullah, R. A., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200130s · Cited by 64
Lisboa, S. F. D. S., Resstel, L. B. M., de Aguiar, D. C., & Guimarães, F. S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.07.032 · Cited by 70
Cognitive enhancers for anxiety disorders
Hofmann, S. G., Smits, J. A. J., Asnaani, A., Gutner, C. A., & Otto, M. W. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.11.020 · Cited by 68
The effects of cannabinoids on contextual conditioned fear in CB1 knockout and CD1 mice
Mikics, ?., Dombi, T., Barsv??ri, B., Varga, B., Ledent, C., Freund, T. F., & Haller, J. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200605000-00003 · Cited by 62
A cortico-amygdala neural substrate for endocannabinoid modulation of fear extinction
Gunduz‐Cinar, O., Castillo, L. I., Xia, M. Y., Leer, E. V., Brockway, E. T., Pollack, G. A., Yasmin, F., Bukalo, O., Limoges, A., Oreizi-Esfahani, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.06.023 · Cited by 68
Haney, M., & Evins, A. E. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.251 · Cited by 68
Bisogno, T., & Marzo, V. D. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.002 · Cited by 68
Micale, V., Stepan, J., Jurik, A., Pamplona, F. A., Marsch, R., Drago, F., Eder, M., & Wotjak, C. T. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.02.002 · Cited by 65
Shallcross, J., Hámor, P. U., Bechard, A. R., Romano, M., Knackstedt, L. A., & Schwendt, M. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00091 · Cited by 65
The Endocannabinoid System and Anxiety
Lisboa, S. F. D. S., Gomes, F. V., Terzian, A. L. B., de Aguiar, D. C., Moreira, F. A., Resstel, L. B. M., & Guimarães, F. S. (2016) · Vitamins and hormones · doi:10.1016/bs.vh.2016.09.006 · Cited by 65
Dopamine, endocannabinoids and their interaction in fear extinction and negative affect in PTSD
Ney, L. J., Akhurst, J., Bruno, R., Laing, P. A. F., Matthews, A. J., & Felmingham, K. L. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110118 · Cited by 63
Ramikie, T. S., & Patel, S. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.037 · Cited by 62
“…and other cortical structures, whereas low CB1-expressing cells are more evenly distributed and found within both the BLA and centromedial nuclei (Mailleux and Vanderhaeghen, 1992; Matsuda et al., 1993; Marsicano and Lutz, 1999; Chhatwal et al., 2005; Hermann and Lutz, 2005; Yoshida et al., 2011).”
InfluentialPharmacological enhancement of fear reduction: preclinical models
Graham, B. M., Langton, J. M., & Richardson, R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01175.x · Cited by 55
The cannabinoid CB1 receptor is expressed on serotonergic and dopaminergic neurons
Lau, T., & Schloss, P. D. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.09.022 · Cited by 62
Stern, C. A. J., de Carvalho, C. R., Bertoglio, L. J., & Takahashi, R. N. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.07.018 · Cited by 62
Ratano, P., Petrella, C., Forti, F., Passeri, P. P., Morena, M., Palmery, M., Trezza, V., Severini, C., & Campolongo, P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.030 · Cited by 61
Lin, Q., Yang, Q., Liu, D., Sun, Z., Dang, H., Liang, J., Wang, Y., Chen, J., & Li, S. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.07.011 · Cited by 60
Bowers, M. E., & Ressler, K. J. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.225 · Cited by 60
Self-citationRatano, P., Everitt, B. J., & Milton, A. L. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.103 · Cited by 60
Cognitive enhancers for facilitating drug cue extinction: Insights from animal models
Nic Dhonnchadha, B. Á., & Kantak, K. M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.01.018 · Cited by 58
Saito, V. M., Wotjak, C. T., & Moreira, F. A. (2010) · PubMed · Cited by 60
Rabinak, C. A., Blanchette, A., Zabik, N. L., Peters, C., Marusak, H. A., Iadipaolo, A., & Elrahal, F. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05499-8 · Cited by 56
Hupli, A. (2018) · Medical Cannabis and Cannabinoids · doi:10.1159/000495307 · Cited by 57
Tailoring therapeutic strategies for treating posttraumatic stress disorder symptom clusters
Norrholm, S., & Jovanovic, T. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s10951 · Cited by 56
Chronic cannabinoid administration in vivo compromises extinction of fear memory
Lin, H.-C., Mao, S.-C., Chen, P.-S., & Gean, P.-W. (2008) · Learning & Memory · doi:10.1101/lm.1081908 · Cited by 48
Lisboa, S. F., Vila-Verde, C., Rosa, J., Uliana, D. L., Stern, C. A. J., Bertoglio, L. J., Resstel, L. B., & Guimaraes, F. S. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5127-x · Cited by 54
Rabinak, C., & Phan, K. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990437 · Cited by 46
Chegini, H., Nasehi, M., & Zarrindast, M. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.12.007 · Cited by 54
The effects of yohimbine and amphetamine on fear expression and extinction in rats
Mueller, D., Olivera-Figueroa, L. A., Pine, D. S., & Quirk, G. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1491-x · Cited by 49
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
Navarro, D., Gasparyan, A., Navarrete, F., Torregrosa, A. B., Rubio, G., Marín, M., Acosta, G. B., García‐Gutiérrez, M. S., & Manzanares, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094764 · Cited by 53
Vagus nerve stimulation as a tool for enhancing extinction in exposure-based therapies
Noble, L. J., de Souza, R. R., & McIntyre, C. K. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4994-5 · Cited by 53
Endocannabinoid regulation of relapse mechanisms
Fattore, L., Fadda, P., & Fratta, W. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.004 · Cited by 51
Sink, K. S., Segovia, K. N., Collins, L. E., Markus, E. J., Vemuri, K. V., Makriyannis, A., & Salamone, J. D. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.03.011 · Cited by 49
Cannabinoids as therapeutics for PTSD
Sbarski, B., & Akirav, I. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107551 · Cited by 49
Manwell, L. A., Satvat, E., Lang, S. T., Allen, C. P., Leri, F., & Parker, L. A. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.08.002 · Cited by 48
Tian, S., Gao, J., Han, L., Fu, J., Li, C., & Li, Z. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.03.005 · Cited by 48
Effects of ∆9-tetrahydrocannabinol on aversive memories and anxiety: a review from human studies
Raymundi, A. M., da Silva, T. R., Sohn, J. M. B., Bertoglio, L. J., & Stern, C. A. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02813-8 · Cited by 40
Zaniewska, M., McCreary, A. C., Przegaliński, E., & Filip, M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.04.034 · Cited by 48
Zer‐Aviv, T. M., Segev, A., & Akirav, I. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000253 · Cited by 47
Ratano, P., Palmery, M., Trezza, V., & Campolongo, P. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00200 · Cited by 46
Viveros, M., Marco, E. M., Llorente, R., & Lamota, L. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282d28fb4 · Cited by 46
Rimonabant: endocannabinoid inhibition for the metabolic syndrome
Wierzbicki, A. S. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01210.x · Cited by 46
Xing, G., Carlton, J. R., Jiang, X., Wen, J., Jia, M., & Li, H. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00161 · Cited by 45
The Use of Medicinal Marijuana for Posttraumatic Stress Disorder: A Review of the Current Literature
Yarnell, S. C. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.15r01786 · Cited by 45
Hill, M. N., Haney, M., Hillard, C. J., Karhson, D. S., & Vecchiarelli, H. A. (2023) · Psychological Medicine · doi:10.1017/s0033291723002465 · Cited by 44
Flavell, C. R., Lambert, E. A., Winters, B. D., & Bredy, T. W. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00214 · Cited by 44
The endocannabinoid system in the amygdala and modulation of fear
Gunduz‐Cinar, O. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110116 · Cited by 45
Pardon, M.-C., Sarmad, S., Rattray, I., Bates, T. E., Scullion, G. A., Marsden, C. A., Barrett, D. A., Lowe, J., & Kendall, D. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.10.002 · Cited by 39
Segev, A., & Akirav, I. (2011) · Learning & Memory · doi:10.1101/lm.2110511 · Cited by 41
Metadata
- Authors
- Chhatwal, J. P., Davis, M., Maguschak, K. A., & Ressler, K. J.
- Affiliations
- Emory University (US)
- Corresponding author
- Ressler, Kerry J
- Venue
- Neuropsychopharmacology
- Published
- 2004-12-22
- Volume
- 30
- Issue
- 3
- Pages
- 516-524
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1987096289
- Cited by
- 376
- References
- 49
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 4 · 2023: 20 · 2022: 7 · 2021: 9 · 2020: 16 · 2019: 12 · 2018: 16 · 2017: 15 · 2016: 19 · 2015: 24 · 2014: 26 · 2013: 23 · 2012: 14
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- National Institutes of Health (MH47840)
- National Institute of Mental Health (MH 47840, F30MH070218, MH070218, MH69884, K01MH069884)
- National Institute of General Medical Sciences (T32GM008169)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- endocannabinoid system, CB1 receptor, fear-potentiated startle, rimonabant, AM404, WIN 55,212-2, fear extinction, anxiety disorders, post-traumatic stress disorder, fear reconsolidation, emotional learning, exposure therapy
- MeSH terms
- Amygdala, Animals, Extinction, Psychological, Fear, Male, Synaptic Transmission, Rats, Sprague-Dawley, In Situ Hybridization, Receptor, Cannabinoid, CB1, Rats, Cannabinoid Receptor Modulators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.